# Liquidia Corp: financial statements, quarterly LQDA · Nasdaq · CIK 1819576 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lqda.md) · [Financials](/companies/lqda/financials.md) · [Filings](/companies/lqda/filings.md) · [Insiders](/companies/lqda/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lqda/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.7](/filings/0001558370-24-015433.md) | [4.5 d](/filings/0001104659-26-023804.md) | [3.0](/filings/0001558370-25-006848.md) | [3.7](/filings/0001558370-25-011139.md) | [4.4](/filings/0001104659-25-105215.md) | [2.9 d](/filings/0001104659-26-023804.md) | [3.1](/filings/0001104659-26-058252.md) | [8.8](/filings/0001104659-26-094410.md) | [54.3](/filings/0001104659-25-105215.md) | [92.0 d](/filings/0001104659-26-023804.md) | [133](/filings/0001104659-26-058252.md) | [172](/filings/0001104659-26-094410.md) | | Cost of revenue | $m | [0.6](/filings/0001558370-24-015433.md) | [1.0 d](/filings/0001558370-25-003237.md) | [1.5](/filings/0001558370-25-006848.md) | [1.5](/filings/0001558370-24-011206.md) | [1.6](/filings/0001558370-24-015433.md) | [1.4 d](/filings/0001558370-25-003237.md) | [1.5](/filings/0001558370-25-006848.md) | not reported | not reported | not reported | not reported | not reported | | Research and development | $m | [7.4](/filings/0001558370-24-015433.md) | [12.8 d](/filings/0001104659-26-023804.md) | [10.1](/filings/0001558370-25-006848.md) | [9.4](/filings/0001558370-25-011139.md) | [11.9](/filings/0001104659-25-105215.md) | [16.5 d](/filings/0001104659-26-023804.md) | [7.0](/filings/0001104659-26-058252.md) | [6.0](/filings/0001104659-26-094410.md) | [9.3](/filings/0001104659-25-105215.md) | [16.9 d](/filings/0001104659-26-023804.md) | [12.6](/filings/0001104659-26-058252.md) | [17.2](/filings/0001104659-26-094410.md) | | Selling, general and administrative | $m | not reported | not reported | not reported | [19.9](/filings/0001558370-25-011139.md) | [20.2](/filings/0001104659-25-105215.md) | [21.2 d](/filings/0001104659-26-023804.md) | [30.1](/filings/0001104659-26-058252.md) | [38.8](/filings/0001104659-26-094410.md) | [40.1](/filings/0001104659-25-105215.md) | [48.2 d](/filings/0001104659-26-023804.md) | [46.9](/filings/0001104659-26-058252.md) | [57.4](/filings/0001104659-26-094410.md) | | Operating income | $m | [(14.9)](/filings/0001558370-24-015433.md) | [(26.4) d](/filings/0001104659-26-023804.md) | [(28.8)](/filings/0001558370-25-006848.md) | [(27.2)](/filings/0001558370-25-011139.md) | [(29.2)](/filings/0001104659-25-105215.md) | [(36.1) d](/filings/0001104659-26-023804.md) | [(35.4)](/filings/0001104659-26-058252.md) | [(37.5)](/filings/0001104659-26-094410.md) | [1.8](/filings/0001104659-25-105215.md) | [19.8 d](/filings/0001104659-26-023804.md) | [61.5](/filings/0001104659-26-058252.md) | [85.5](/filings/0001104659-26-094410.md) | | Interest expense | $m | [1.8](/filings/0001558370-24-015433.md) | [2.0 d](/filings/0001558370-24-003051.md) | [2.5](/filings/0001558370-24-007991.md) | [2.6](/filings/0001558370-24-011206.md) | [3.0](/filings/0001558370-24-015433.md) | [6.5 d](/filings/0001104659-26-023804.md) | [4.7](/filings/0001104659-26-058252.md) | [5.7](/filings/0001104659-26-094410.md) | [6.9](/filings/0001104659-25-105215.md) | [6.9 d](/filings/0001104659-26-023804.md) | [6.5](/filings/0001104659-26-058252.md) | [6.3](/filings/0001104659-26-094410.md) | | Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-058252.md) | [0.0](/filings/0001104659-26-094410.md) | not reported | not reported | [3.9](/filings/0001104659-26-058252.md) | [7.0](/filings/0001104659-26-094410.md) | | Net income | $m | [(15.8)](/filings/0001558370-24-015433.md) | [(27.5) d](/filings/0001104659-26-023804.md) | [(30.1)](/filings/0001104659-25-105215.md) | [(28.7)](/filings/0001104659-25-105215.md) | [(31.0)](/filings/0001104659-25-105215.md) | [(38.5) d](/filings/0001104659-26-023804.md) | [(38.4)](/filings/0001104659-26-094410.md) | [(41.6)](/filings/0001104659-26-094410.md) | [(3.5)](/filings/0001104659-25-105215.md) | [14.6 d](/filings/0001104659-26-023804.md) | [52.9](/filings/0001104659-26-094410.md) | [74.7](/filings/0001104659-26-094410.md) | | Diluted EPS | $ per share | [(0.24)](/filings/0001558370-24-015433.md) | not reported | [(0.40)](/filings/0001558370-25-006848.md) | [(0.38)](/filings/0001558370-25-011139.md) | [(0.40)](/filings/0001104659-25-105215.md) | not reported | [(0.45)](/filings/0001104659-26-058252.md) | [(0.49)](/filings/0001104659-26-094410.md) | [(0.04)](/filings/0001104659-25-105215.md) | not reported | [0.52](/filings/0001104659-26-058252.md) | [0.74](/filings/0001104659-26-094410.md) | | Basic EPS | $ per share | [(0.24)](/filings/0001558370-24-015433.md) | not reported | [(0.40)](/filings/0001558370-25-006848.md) | [(0.38)](/filings/0001558370-25-011139.md) | [(0.40)](/filings/0001104659-25-105215.md) | not reported | [(0.45)](/filings/0001104659-26-058252.md) | [(0.49)](/filings/0001104659-26-094410.md) | [(0.04)](/filings/0001104659-25-105215.md) | not reported | [0.60](/filings/0001104659-26-058252.md) | [0.84](/filings/0001104659-26-094410.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [76.2](/filings/0001558370-23-017842.md) | [83.7](/filings/0001558370-25-003237.md) | [158](/filings/0001558370-24-007991.md) | [133](/filings/0001558370-24-011206.md) | [204](/filings/0001558370-24-015433.md) | [176](/filings/0001104659-26-023804.md) | [170](/filings/0001558370-25-006848.md) | [173](/filings/0001558370-25-011139.md) | [157](/filings/0001104659-25-105215.md) | [191](/filings/0001104659-26-094410.md) | [223](/filings/0001104659-26-058252.md) | [284](/filings/0001104659-26-094410.md) | | Current assets | $m | [83.0](/filings/0001558370-23-017842.md) | [89.9](/filings/0001558370-25-003237.md) | [168](/filings/0001558370-24-007991.md) | [147](/filings/0001558370-24-011206.md) | [214](/filings/0001558370-24-015433.md) | [185](/filings/0001104659-26-023804.md) | [177](/filings/0001558370-25-006848.md) | [196](/filings/0001558370-25-011139.md) | [227](/filings/0001104659-25-105215.md) | [273](/filings/0001104659-26-094410.md) | [333](/filings/0001104659-26-058252.md) | [438](/filings/0001104659-26-094410.md) | | Total assets | $m | [112](/filings/0001558370-23-017842.md) | [118](/filings/0001558370-25-003237.md) | [197](/filings/0001558370-24-007991.md) | [177](/filings/0001558370-24-011206.md) | [253](/filings/0001558370-24-015433.md) | [230](/filings/0001104659-26-023804.md) | [227](/filings/0001558370-25-006848.md) | [257](/filings/0001558370-25-011139.md) | [276](/filings/0001104659-25-105215.md) | [328](/filings/0001104659-26-094410.md) | [402](/filings/0001104659-26-058252.md) | [522](/filings/0001104659-26-094410.md) | | Current liabilities | $m | [12.2](/filings/0001558370-23-017842.md) | [18.6](/filings/0001558370-25-003237.md) | [21.9](/filings/0001558370-24-007991.md) | [24.2](/filings/0001558370-24-011206.md) | [33.8](/filings/0001558370-24-015433.md) | [41.8](/filings/0001104659-26-023804.md) | [60.5](/filings/0001558370-25-006848.md) | [78.4](/filings/0001558370-25-011139.md) | [103](/filings/0001104659-25-105215.md) | [136](/filings/0001104659-26-094410.md) | [150](/filings/0001104659-26-058252.md) | [189](/filings/0001104659-26-094410.md) | | Total liabilities | $m | [63.6](/filings/0001558370-23-017842.md) | [71.0](/filings/0001558370-25-003237.md) | [100](/filings/0001558370-25-006848.md) | [115](/filings/0001558370-24-011206.md) | [142](/filings/0001558370-24-015433.md) | [151](/filings/0001104659-26-023804.md) | [178](/filings/0001558370-25-006848.md) | [242](/filings/0001558370-25-011139.md) | [254](/filings/0001104659-25-105215.md) | [283](/filings/0001104659-26-094410.md) | [293](/filings/0001104659-26-058252.md) | [327](/filings/0001104659-26-094410.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [48.0](/filings/0001558370-24-015433.md) | [47.3](/filings/0001104659-26-023804.md) | [97.1](/filings/0001104659-25-105215.md) | [72.8](/filings/0001104659-25-105215.md) | [113](/filings/0001104659-25-105215.md) | [79.4](/filings/0001104659-26-094410.md) | [49.7](/filings/0001104659-26-094410.md) | [15.2](/filings/0001104659-26-094410.md) | [22.1](/filings/0001104659-25-105215.md) | [44.7](/filings/0001104659-26-094410.md) | [109](/filings/0001104659-26-094410.md) | [195](/filings/0001104659-26-094410.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(11.6) d](/filings/0001558370-24-015433.md) | [(16.0) d](/filings/0001104659-26-023804.md) | [(24.9)](/filings/0001558370-25-006848.md) | [(22.7) d](/filings/0001558370-25-011139.md) | [(25.1) d](/filings/0001104659-25-105215.md) | [(20.8) d](/filings/0001104659-26-023804.md) | [(30.7)](/filings/0001104659-26-058252.md) | [(39.5) d](/filings/0001104659-26-094410.md) | [(9.8) d](/filings/0001104659-25-105215.md) | [44.2 d](/filings/0001104659-26-023804.md) | [53.0](/filings/0001104659-26-058252.md) | [80.2 d](/filings/0001104659-26-094410.md) | | Capital expenditure | $m | [0.5 d](/filings/0001558370-24-015433.md) | [0.2 d](/filings/0001104659-26-023804.md) | [0.6](/filings/0001558370-25-006848.md) | [1.3 d](/filings/0001558370-25-011139.md) | [1.7 d](/filings/0001104659-25-105215.md) | [1.3 d](/filings/0001104659-26-023804.md) | [0.3](/filings/0001104659-26-058252.md) | [1.1 d](/filings/0001104659-26-094410.md) | [0.9 d](/filings/0001104659-25-105215.md) | [2.0 d](/filings/0001104659-26-023804.md) | [2.8](/filings/0001104659-26-058252.md) | [11.2 d](/filings/0001104659-26-094410.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [64.5](/filings/0001558370-23-017842.md) | [64.7](/filings/0001558370-24-007991.md) | [64.8](/filings/0001558370-24-011206.md) | [64.9](/filings/0001558370-24-015433.md) | [75.4](/filings/0001558370-25-006848.md) | [76.4](/filings/0001558370-25-011139.md) | [78.3](/filings/0001104659-25-105215.md) | [85.2](/filings/0001104659-26-058252.md) | [85.6](/filings/0001104659-26-094410.md) | [86.3](/filings/0001104659-25-105215.md) | [101](/filings/0001104659-26-058252.md) | [101](/filings/0001104659-26-094410.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 89,508,891 at 2026-07-29, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094410.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.